Recro Pharma Inc (NASDAQ:REPH) has received an average recommendation of “Buy” from the seven analysts that are presently covering the firm. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $18.00.

Several research analysts recently commented on the company. Zacks Investment Research cut Recro Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 14th. Aegis reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a research report on Monday, March 27th.

Shares of Recro Pharma (NASDAQ:REPH) traded down 1.13% during mid-day trading on Monday, hitting $7.90. 73,984 shares of the company traded hands. Recro Pharma has a 52-week low of $5.89 and a 52-week high of $12.50. The firm’s market cap is $150.50 million. The firm has a 50-day moving average price of $7.97 and a 200 day moving average price of $7.73.

ILLEGAL ACTIVITY NOTICE: “Recro Pharma Inc (REPH) Receives $18.00 Consensus Price Target from Analysts” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/04/20/recro-pharma-inc-reph-receives-18-00-consensus-price-target-from-analysts.html.

In other news, major shareholder Scp Vitalife Partners (Israel) sold 4,030 shares of the firm’s stock in a transaction on Thursday, February 16th. The stock was sold at an average price of $7.89, for a total value of $31,796.70. Following the completion of the sale, the insider now directly owns 772,714 shares in the company, valued at $6,096,713.46. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Scp Vitalife Partners Ii Lp sold 9,983 shares of the firm’s stock in a transaction on Friday, February 17th. The shares were sold at an average price of $7.59, for a total value of $75,770.97. Following the completion of the sale, the insider now owns 2,292,899 shares of the company’s stock, valued at $17,403,103.41. The disclosure for this sale can be found here. Insiders have sold 58,990 shares of company stock valued at $467,384 over the last quarter. Corporate insiders own 39.30% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its stake in shares of Recro Pharma by 56.0% in the third quarter. Wells Fargo & Company MN now owns 31,200 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 11,200 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Recro Pharma during the fourth quarter worth $118,000. Acadian Asset Management LLC acquired a new stake in shares of Recro Pharma during the third quarter worth $140,000. Marshall Wace LLP raised its stake in shares of Recro Pharma by 17.4% in the fourth quarter. Marshall Wace LLP now owns 177,923 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after buying an additional 26,377 shares during the period. Finally, Opus Point Partners Management LLC acquired a new stake in shares of Recro Pharma during the fourth quarter worth $322,000. Institutional investors own 53.23% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Stock Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related stocks with our FREE daily email newsletter.